PEP-CMV vaccine

BIOLOGICAL2 trials

Sponsors

Charlotte Lemech, Washington University School of Medicine

Conditions

Diffuse Midline GliomaDiffuse Midline High-grade GliomaEpendymomaGlioblastomaMedulloblastoma

Phase 1

Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma

RecruitingNCT06132438

Charlotte LemechGlioblastoma

Start: 2024-07-22End: 2027-09-01Target: 26Updated: 2026-09-15

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

SuspendedNCT06639607

Washington University School of MedicineDiffuse Midline Glioma, Diffuse Midline High-grade Glioma, Ependymoma +1

Start: 2026-09-30End: 2051-06-30Target: 68Updated: 2026-09-11

Related Papers

TIP-19. INTERROGATE-GBM Phase I trial: Immunotherapy peptide vaccine targeting cytomegalovirus (CMV) antigens in glioblastoma

Neuro-Oncology2025-11-01